Peeling Back the Band-Aid: Johnson & Johnson

Author:
Publish date:
Video Duration:
0

Curious about the company that's making  headlines this morning?

Johnson & Johnson (JNJ) - Get Report  reported earnings before the opening bell on Tuesday, July 16.

The company posted a stronger-than-expected second quarter for 2019 and boosted its full-year sales outlook as international pharmaceutical revenues offset a domestic pullback.

Here are some other highlights:

  • Adjusted diluted earnings for the three months ending in June 2019 came in at $2.58 per share, up 22.8% from the same period last year.
  • Reported group revenues fell 1.3% to $20.56 billion but beat analysts' forecasts of $20.39 billion.
  • Looking into 2019, operational sales are to grow to 3.7%, up from a prior forecast of between 2% and 3%, guiding for a topline of $82.4 billion to $83.2 billion.
  • U.S consumer sales rose 4.1% to $1.537 billion, but domestic pharmaceutical sales fell 2% to $5.78 billion.

Watch the video to learn about the company's history and how it became what it is today.

Related. Johnson & Johnson Tops Q2 Earnings Estimate, Boosts 2019 Sales Forecast

What the Upcoming Earnings Season Means for Investors